Undisclosed Target 2

Undisclosed Target 2 is a placeholder designation frequently utilized within the biotechnology and pharmaceutical industries to identify therapeutic targets that are in active development but whose specific molecular identities remain proprietary. This label is commonly found in the pipelines of several companies, including Vincerx Pharma [3], Harbour BioMed [4, 6], PTC Therapeutics [10], Amaroq Therapeutics [1], and Geneos Therapeutics [2]. The designation represents a diverse array of biological entities depending on the company's platform; for instance, in Vincerx Pharma's pipeline, it refers to a cell-surface antigen targeted by a Kinesin Spindle Protein inhibitor (KSPi) antibody-drug conjugate (ADC) for solid tumors [3, 8]. In contrast, PTC Therapeutics uses the term for a target within its small molecule splicing modulation platform [10, 11], and Amaroq Therapeutics applies it to a long non-coding RNA (lncRNA) target in oncology [1]. Because the name does not map to a single canonical protein or nucleic acid, it is classified as an incorrect or placeholder entry in structured target databases. Analysts typically monitor these designations for future disclosure of the specific receptor, enzyme, or gene as the associated drug candidates progress into clinical stages.

Other names

Target 2Undisclosed Target

Varies by therapeutic program; includes kinesin spindle protein inhibition via antibody-drug conjugate (ADC) delivery [3], multispecific antibody binding [6], and small molecule-mediated RNA splicing modulation [10].